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Abstract
Background Sarcopenia is a significant geriatric syndrome
with both health care expenditure and personal burden. Most
recently, the EuropeanWorking Group in Sarcopenia in Older
Adults has established a consensus definition and assessment
criteria for sarcopenia that includes a below-normal muscle
mass and muscle function (either or both of below-normal
muscle strength and physical performance). Using these
criteria, work is needed to identify the prevalence and risk
factors among the old, and those most susceptible to
sarcopenia, the very old. This manuscript describes the re-
cruitment and data collection methodology, and direct burden
to participants, among a very old cohort residing in a residen-
tial aged care (RAC) setting.
Methods Eleven RAC facilities participated in the study. Po-
tential participants were identified by the facility service man-
ager and then randomised into the study. All participants gave
self or substitute decision maker consent. Participants under-
took a single one on one assessment that included measures of
sarcopenia, functional capacity, cognitive and nutritional
health, falls, activity, facility and hospital history, physical
activity and assessment burden. A sub-study of physical ac-
tivity and sedentary behaviours measured by activPAL3™
inclinometer was also conducted.
Results Of 709 residents, 328 were ineligible to participate.
Two hundred and seventy-three residents were randomised to
the study and 102 gave informed or substitute decision maker
consent. Participants were 84.5±8.2 years of age and had been
in care for 1,204.2±1,220.1 days. The groups need for care
was high (Aged Care Funding Instrument score of 2.6±1.7)
and they had a below-normal functional (Short Physical Per-
formance Battery summery score of 3.5±2.4). The larger
percentage of participants had no depression and normal
cognitive capacity. A total of 33 residents participated in the
activPAL study. Each assessment took an average of 27.0±
7.0 min, with a low assessment burden reported by
participants.
Conclusions The successful assessment of sarcopenia and
physical activity in a RAC setting is labour intensive to
establish, but feasible to conduct. Low recruitment numbers
and the restrictive exclusion criteria, may have limited the
accuracy of this work. However, this work is a primary step
in establishing the level of sarcopenia and its risk factors for
those in end-of-life care.
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1 Introduction
Over the next two decades, the direct cost of residential aged
care (RAC) service expenditure in Australia will increase
substantially compared with other primary health services
due to population ageing and an increased prevalence of
complex health conditions such as dementia ($8 billion),
cardiovascular disease ($1.9 billion) and musculoskeletal dis-
orders ($1.7 billion) [1]. When coupled with increasing need
for intensive RAC services and the growth of the ≥85 years
population to 3.1 million by 2054 [2], the economic impact
will be substantial. A primary cause in institutionalisation is
the age-associated loss in muscle mass and muscle function,
termed sarcopenia [3, 4].
Sarcopenia is a significant geriatric syndrome, a major
cause of disability and increasing healthcare utilisation that
cost the US health care system>$US18.5 billion in 2000 [4,
5]. Recently, due to a lack of term clarity, a number of
international organisations have been working to establish a
consensus definition. Among these, the European Working
Group on Sarcopenia in Older People (EWGSOP) have de-
veloped a definition and diagnostic criteria that required the
presence of both low muscle mass and low muscle function
(muscle strength or physical performance) [6]. While earlier
interpretations had evaluated sarcopenia as an age-associated
decline in muscle mass alone, a recognised precursor to dis-
ease and disability, it is the loss in muscle function which has
the most debilitating consequences for later life disability [7].
In particular, for those in end-of-life care (residential aged care
or a nursing home) declining functional muscle strength and
physical performance equate directly to increased dependency
and care needs [8]. Previous research had estimated the prev-
alence of sarcopenia to be 6–50 % among the very old [5, 9,
10]. Using the revised EWGSOP definition and assessment
criteria, a prevalence of 33 % among very old adults has been
shown [11, 12]. However, prevalence may be under-estimated
due to the exclusion of the disabled, bedridden, non-
ambulatory or those with advanced disease [3]. With this,
the population assumed to be most vulnerable, those in end-
of-life care are significantly understudied in relation to
prevalence.
Several factors lead to the onset and progression of
sarcopenia including muscular disuse and age-related alter-
ations in sex hormones, protein synthesis, proteolysis, neuro-
muscular integrity, endocrine function, nutritional balance and
an increase in muscle fat content [13]. Whereas a number of
these mechanisms are well-understood, the effects of lifestyle
choices as risk factors for sarcopenia are less clear [14]. To
date, data are mixed in relation to the influence of body
weight, level of disease, gender, health and physical activity
background. Further, the importance of other factors known to
influence healthy ageing (e.g., education, socioeconomic
background or smoking history) as risk factors for sarcopenia
is currently poorly understood. It is established that reduced
muscle mass, muscle strength and physical performance in-
crease the risk of disability, institutionalisation and mortality
[8]. However, a broader understanding of these as risk factors
in relation to sarcopenia is needed [13]. In addition, physical
inactivity and muscle disuse are suggested to influence the
development of disability later in life [15], but more work is
needed to define the relationship with sarcopenia.
This paper describes the methodologies employed to col-
lect sarcopenia prevalence and risk factor data from old and
very old Australians residing in high- and low-care RAC. In
addition to the recruitment and assessment strategies, we
describe participation burden. Given the renewed interest in
the area of sarcopenia due to its detrimental effect on disability
and associated economic burden, the updated diagnostic
criteria and the difficulty recruiting frail older people, this
paper reports a detailed protocol on recruitment strategy and
collecting information on risk factors and prevalence of
sarcopenia within residential care settings, and may serve as
valuable guide for others looking to collect data in a similar
setting. The aims of the present study were to establish the
prevalence and risk factors to sarcopenia among a group of
older adults with compromised wellbeing residing in RAC
facilities. As a risk factor to sarcopenia, the use of an
activPAL3™ motion inclinometer was trialled, and study
feasibility was assessed through participant burden.
2 Methods
2.1 Study design and recruitment
A cross-sectional study with random sampling was undertak-
en to measure the prevalence of sarcopenia and its association
with functional and clinical risk factors in older adults residing
in RAC facilities. Eleven purposefully selected RAC facilities
within one care organisation and a 100-km radius of Bond
University, Gold Coast, in South East Queensland, Australia,
were identified and invited to participate. At pre-organised
times, facilities were visited by members of the research team
and a discussion undertaken with the facilities Service Man-
ager or Director of Nursing as to the eligibility of all residents
to participate in the study. Inclusion criteria were (i) age over
60 years, (ii) residing in a RAC facility and (iii) could provide
informed consent, or if unable, proxy-informed consent ob-
tained from the substitute decision maker. Residents were
excluded if, (i) they had a pacemaker due to reported contra-
indications to bioelectrical impedance analysis, (ii) they
were end-stage palliative or terminal (iii), they had diffi-
cult behaviours that would limit data collection or (iv)
they had medical or other issues that would limit data
collection. Medical issues raised as a reason for
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exclusion were total uncommunicable deafness and sig-
nificantly advanced dementia or a comatose status.
Eligible participant were randomly selected within three
levels of care (low- and high-care or residing in a secure
dementia ward). Randomisation was undertaken using a ran-
dom number generator (http://stattrek.com/statistics/random-
number-generator.aspx). Reasons for ineligibility or refusal to
participate were recorded. The study was approved by the
human ethics committees of UnitingCare Queensland, Bond
University and the University of Queensland.
Following randomisation, at a pre-organised time, facilities
were re-visited and participant information sheet and consent
forms delivered to the service manager or director of nursing.
In addition, facilities were supplied with a list of residents
randomised to participate and an instruction document
outlining information sheet dissemination and consent. In
brief, facilities were asked to deliver the information sheet to
the participant with a request for the participant to read and
sign the consent form if interested. For those cognitively
challenged participants, the facility service manager or direc-
tor of nursing was asked to contact the substitute decision
maker, inform them of the study and inform them of the need
for consent for participation. All participants were required to
give informed consent directly or by the substitute decision
maker, or by the service manager or director of nursing
following discussion with the substitute decision maker. Fa-
cilities were then followed up 1 week later and a date set for
participant assessments to take place. All participants were de-
identified and assigned a study registration number.
2.2 Data collection
At a pre organised time, the study research assistant (RA), an
experienced allied health professional, met with the facility’s
service manager and resident nurse to establish the level of
care required for each participant. Following this discussion, a
carer accompanied the RA to visit and make the initial contact
with the participants. For low-care participants, the RA was
then left to conduct the data collection without assistance. For
high-care and dementia participants, the carer remained.
Where necessary and with the aim of a reduced falls risk,
carers assisted the RAwith any physical mobilisation of high
care and dementia participants. In addition, for dementia
participants, the carer was specifically from the participants
ward. Their presence served to increase familiarity for the
participants and thereby reduce anxiety, and to help the RA
identify assessment components, the participant was unable to
complete. Participants were assessed individually in a one-on-
one format, and data were collected from all participants at
one facility before moving to the next facility. To reduce any
potential burden to participants undertaking assessment, par-
ticipants were encouraged to rest as needed and were given
verbal support and encouragement.
2.3 Measures
Although facility staff had previously familiarised participants
with the project, the RA reviewed these documents before
commencing the assessment. Participants who did not provide
consent were asked a short series of questions about why they
did not want to participate, and then thanked for their time. All
measures are validated for use among old and very old adults.
Data for each participant was entered on site and then
forwarded to the project manager at Bond University at the
completion of each day. Prevalence was determined using the
project’s primary outcome of sarcopenic status and the
EWGSOP definition and assessment criteria [6]. Secondary
measures were collected to determine risk factors for
sarcopenia in this population. In case a participant was unable
to undertake a physical measure, self-report or answer a
question, this variable was left blank, except for the 2.4-m
walk which was scored as 100 s to ensure a walking speed of
<0.8 m/s and that they were scored 0 for this component of the
Short Physical Performance Battery (SPPB) summary score.
2.3.1 Primary outcome: sarcopenic status
According to the EWGSOP, the diagnosis of sarcopenia re-
quires the presence of both low muscle mass and low muscle
function (muscle strength or physical performance). In accor-
dance with EWGSOP and appropriate for use among very old
low functioning adults, (a) muscle mass was measured using
Bioelectrical Impedance Analysis (BIA), (b) muscle strength
by hand grip strength and (c) performance by the SPPB 2.4-m
walk [11]. The cut-off point to define low muscle mass are ≥2
standard deviations below the norm of a young healthy pop-
ulation, to define low muscle strength are <30 and <20 kg for
men and women, respectively, and to define low physical
performance is a gait speed of <0.8 m/s [6].
BIA (Maltron BF-906, Maltron International Ltd., Ray-
leigh, UK) is a non-invasive, non-intrusive diagnostic system
that estimates the volume of fat and lean body mass, BMI and
resistance (ohms). Participants lay supine during testing, with
electrodes placed at the top of the right wrist and distal end of
the central metacarpal, and over the right foot talus and distal
end of the central metatarsal.
Muscle mass is calculated from the BIA equation of
Janssen et al.[5], namely, skeletal muscle mass (kg)=[height
(cm)2/BIA resistance (ohms)×0.401)+(gender×3.825)+(age
(years)×−0.071)]+5.102. BIA was deemed as the most ap-
propriated measure for this group, given their limited mobility
and function, and the difficulties in transport participant to an
offsite venue and the invasive nature of dual-energy x-ray
absorptiometry (DXA) for this cohort.
Handgrip muscle strength was measured by isometric
Jamar dynamometer (Sammons Preston Rolyan, Boling-
brook, IL). Three trials were conducted for dominant hand
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and the best result used in analysis. Participants were seated,
instructed to keep their elbow at 90 ° and to squeeze the
dynamometer maximally [16].
Physical performance was measured by the SPPB 2.4-m
walk test [17, 18]. This measure was selected in preference to
the 4 or 6 m, due to the convenience of assessing participants
in the confines of their own room, most of which had restrict-
ed space [19]. In addition, the two other SPPB measures
where collected. The additional two tests for the SPPB are
(1) the hierarchical test of standing balance and (2) the five-
time repeated chair stands. Measures were collected in tripli-
cate and the best result was used in analysis.
2.3.2 Secondary outcomes
Demographics and health status The RA collected height
(cm) and weight (kg) by standardised methodologies. Demo-
graphics and clinical data including gender, level of education,
occupation or spouse’s occupation if not the primary income
earner, fall history in the last 6 months, history and present
frequency of smoking and exercise. In addition, womenwhere
asked about age of menopause. From facility records, number
and type of diseases and medications were recorded, and from
the organisational database, date of birth and entry into the
facility, marital status, language spoken, hospitalisation histo-
ry and duration of stay in the last 12months, falls history, bone
mineral density diagnosis (normal, osteopenic or osteoporot-
ic) and the Australian Aged Care Funding Instrument (ACFI)
rating at entry and at present were recorded.
Mental health The extent of cognitive impairment and de-
pression were assessed by the Mini-Mental State Examination
questionnaire (MMSE) [20] and the Geriatric Depression
Scale (GDS-15), respectively. The GDS consists of a series
of 15 questions in a simple yes/no format [21]. From MMSE
summary scores, participants were classified as having normal
cognition (25–30), mild (21–24), moderate (14–20) or severe
(<13) cognitive impairment [22]. From GDS summary
scores, participants were classified as without depression
(normal (0–4)), or having mild depression (5–8), moder-
ate depression (9–11) or severe depression (12–15) [21].
Nutritional status The Mini-Nutritional Assessment Instru-
ment (MNA) assesses nutritional status. The MNA consists
of four main components (anthropometric and a global, die-
tary, and subjective assessment) and is a Dieticians Associa-
tion of Australia-recommended screening tool in all levels of
care [23, 24].
Falls history and fear of falling A fall was defined as an event
resulting in a person coming to rest unintentionally on the
ground or lower level, not as a result of a major intrinsic event
(such as a stroke) or an overwhelming hazard [25]. The
Activity-Specific Balance Confidence questionnaire was used
to assess fear of falling [26]. In addition, participants were
asked directly to recall the number of falls they had experi-
enced in the last 6 months as a reference point for comparison
to facility-recorded falls [27].
Facility audit of services and activities All participating facil-
ities underwent a 35-question audit to provide information on
the services and activities accessible and available to partici-
pants. Examples of the services, activities and facilities
audited included ‘doctor or resident nurse’, ‘group exercise
classes’ and ‘swimming pool.’ These were scored as ‘avail-
able’ or ‘not available’.
Participant burden To evaluate the impact of data collection,
participants were asked a short battery of eight questions and
sessions were timed. Questions assessed length and fatigue
during assessment, and clarity of instructions and terminolo-
gy, and were scored on a 5-point Likert Scale (strongly agree,
agree, neither, disagree or strongly disagree). Participants
were also asked whether they would be willing to be involved
in follow-up work and if they required a rest during assess-
ment. The RA noted if participants required more than one
session to collect individual data.
ActivPAL3™ sub-study The activPAL3™ (Pal Technologies
Ltd., Glasgow, UK) is a small (dimensions=53×35×7 mm;
15 g), unobtrusive device/inclinometer worn on the thigh 24 h
per day for the duration of the measurement protocol and
classifies time as sitting/lying, standing or ambulation [28].
All participants in the primary study were invited to partici-
pate in the activPAL3™ sub-study, excluding those with
dementia or non-ambulatory. All participants consent to the
sub-study independent of the primary study. The device was
fitted by the RA to the participant’s anterior mid-line of the
right thigh using a hypoallergenic bandage, and worn contin-
uously for 7 days. If removed, participants and facility staff
were instructed on how to replace the device appropriately.
Sleep times and any time where the activPAL3™ was re-
moved were recorded in a sleep diary. A batch of 10 monitors
were charged, initialised and waterproofed each week then
sent to the RA for distribution to participants. Each monitor
has a recording life of 14 days after the initialised start date.
Following the protocol period, the device was returned to the
research team by centre staff using a reply paid express post
bag. Raw data from the activPAL3™ monitor were used to
generate overall activity averages, as well as per day and per
hour averages. These data are presented elsewhere [29].
In addition to measuring older adult’s activity patterns, the
feasibility of using activPAL3™ monitors in a RAC popula-
tion was investigated. To facilitate this, participants could
express any concerns associated to wearing the monitor by
writing in a designated section of the sleep diary. Further, the
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researchers undertaking this sub-study conducted a telephone
interview with each RAC centre asking them for any com-
ments and/or difficulties experienced due to the monitors. As a
final measure, a research member visited one RAC centre to
personally conduct interviews with the primary contact person
for the study. Questions of concern included, but are not
limited to, ‘did participants report any concerns regarding
wearing the monitor?’, ‘did the process impede on staff
work?’ and ‘what are your suggestions for future studies?’
2.4 Sample size and analysis plan
Based on previous non-consensual sarcopenic prevalence es-
timates of 30 % in RAC [13, 30, 31], and assuming a level of
confidence Z=95 %, and precision of 5 %, it was estimated
that 210 adults would be required for this study [32]. With
allowance for a dropout for 30%, 273 adults were randomised
into the study. The primary aim of this study is to measure the
prevalence of sarcopenia in RAC.
Cases of sarcopenia were diagnosed using the EWGSOP
criteria [6]. Specifically, participants were classified pre-
sarcopenic if found to have below-normal muscle mass only,
sarcopenic if they had below-normal muscle mass and func-
tion (either muscle strength or physical performance), and
severe sarcopenic if they had below-normal muscle mass,
strength and performance [6]. Prevalence was based on a
proportion of cases of sarcopenia per total study population.
Subgroup analyses were conducted on the prevalence of
sarcopenia according to gender, age and care settings. Com-
parisons were made on demographic, functional and clinical
variables between participants with and without sarcopenia.
Data were analysed using parametric and nonparametric sta-
tistics based on data distribution. Risk factors were determined
by statistical analysis of the association of the secondary
measures on the primary measure of sarcopenic status by
regression analysis. Statistical significance was based on
two-tailed tests with p<0.05 considered as significant.
3 Results: baseline characteristics
3.1 Participants
Of the 709 residents residing in the 11 RAC facilities, 328
were considered by facility service managers or directors of
nursing ineligible to participate. The reasons for ineligibility
were: 3 % had a pacemaker, 8 % were end-stage palliative or
terminal, 31 % had dangerous behaviours and 58 % had
medical or other problems that would have made them diffi-
cult to include in data collection, including the inability to get
substitute decision maker consent. Three hundred and eighty-
one residents were considered eligible and capable of partic-
ipating. Of these, 273 were randomly selected to participate in
the study. Within this sample, level of care was represented as
per the total eligible sample (N=381). This was: 29 % low
care, 58 % high care and 13 % in a secure dementia ward. Of
the 273 residents invited to participate, 91 provided consent
and 11 were consented by proxy (N=102; 37 %). Therefore,
of the total available sample, 53 % were eligible for participa-
tion and 14% consented to participate. Participant recruitment
and assessment occurred over October to December 2012. The
flow of recruitment to assessment is represented in Fig. 1.
Reasons for non-consent were (i) ‘didn’t want to partici-
pate’ (79 %), ‘My GP doesn’t want me to participate’ (7 %),
they were not available during the facility testing period (2%),
a change in their situation occurred (generally health related)
(7 %) or they died after being identified as potentially eligible
prior to consent (3 %). Five people claimed they were too sick
on the day of their assessment and four did not provide a
reason.
Participants ranged in age from 60.7 to 101.3 years with the
average age of 84.5±8.2 years and were in the RAC facility
for 1,204.2±1,220.1 days (65–7165 days). Level of disability
and need for care was represented by a group ACFI score of
2.6±1.7 (1 being the highest needs and 7 the lowest),
with low functional status supported by a SPPB score
of 3.5±2.4 (1–11). Participants had an average of 1.8±
2.0 chronic diseases (0–6) and took 11.8±4.9 medica-
tions (2–31). The BMI for participants was 27.4±
5.7 kg/m2 (13.4–44.5 kg/m2). Six participants were un-
able to complete the MMSE and GDS. Of the remaining
group, 33 had normal cognitive capacity, 19 were mildly, 30
moderately and 14 severely cognitively impaired. Nine adults
had severe depression, 13 were moderately and 22 mildly
depressed and the remaining 52 had no depression.
11 RAC facilities (N = 709) approached and recruited.
Resident eligibility determined.
328 Residents not eligible 381 Residents eligible
273 Residents randomly
selected by de-identified
customer number
Information sheets and
consent forms delivered to
facilities for delivery (N =
273) 
Telephone follow-up and
assessment scheduled
Data collected from 91 self-
consenting and 11 substitute
decision maker consented
residents
108 Residents continue with
usual care 
41 Recruited into the
activPAL sub-study
Fig. 1 Project CONSORT diagram of recruitment and assessment
J Cachexia Sarcopenia Muscle (2014) 5:229–236 233
3.2 Burden
Time to complete the data collection ranged from 11.0 to
59.0 min dependant of the participant capacity to complete
measures, with an average of 27.0±7.0 min across the group.
When asked about the burden of assessment, 84 % of partic-
ipants either agreed or strongly agreed that the assessment was
an appropriate length and 83 % either agreed or strongly
agreed that the instructions given with each measure were
clear. In relation to the number of questionnaires, terminology
employed and assessment fatigue, >70 % of participant felt
the assessment protocol was appropriate for the target cohort.
Of those who participated, only one individual required a
break during testing and 87 % said they would be happy to
be followed up for future work in this area.
3.3 ActivPAL sub-study
For the activPAL3™ sub-study, a total of 41 residents agreed
to participate from an eligible 86. Most common reasons for
not consenting were ‘didn’t want to participate’ (73 %) and
‘believe it will be too difficult’ (19 %). Two people were
unavailable during the testing period, one person saw no
benefit to participating, and six residents said ‘My GP doesn’t
want me to participate’. Six monitors were lost during the
course of the study, and two participants were subsequently
found to be ineligible. The final participant sample consisted
of 33 residents. Of those, 2 did not return their diaries, 3 did
not complete the diary, 14 (42 %) partially completed the
diary, and 14 (42 %) completed the diary in full. Five
(15 %) provided at least one comment regarding wearing the
monitor. All comments were positive and participants did not
report any adverse outcomes.
Informal interviews with key contact personnel at each
centre reinforced that residents were not burdened by wearing
the monitor. There were no reported cases of skin irritation or
complaints from residents. Furthermore, staff members indi-
cated the monitor wear did not significantly impede on their
daily duties. Discussions during the face-to-face interview
indicated there was a need to include RAC staff members in
the activPAL3™ process from the very beginning. Further-
more, staff members suggested that more information regard-
ing the monitors and the overall goal of the sub-study would
have been beneficial in order to better explain the study to
residents and answer questions they may have had, and to
avoid confusion and minimise the risk of losing monitors.
4 Discussion
Demonstrated by a topical presence at the 2013 International
Association of Geriatrics and Gerontology Congress and
Global Aging Research Network symposium, sarcopenia is
re-emerging as a growing area of research interest (see Jour-
nal of Nutrition, Health and Aging, Issue 6, Supplementary,
June 2013). While sarcopenia has always generated some
research, the revised European Working Group in Sarcopenia
in Older People diagnostic criteria has significantly influenced
the clinical acknowledgment of the consequences of
sarcopenia, and the association to disease and disability [33].
Using this definition and assessment criteria, more work is
needed at the community and in-care level to establish popu-
lation prevalence and the associated risk factors. This paper
describes in detail the feasibility and processes undertaken in
studying these variables in an Australian population of very
old RAC adults. It is suggested this work could service as a
guide for others interested in undertaking similar research
among other international populations.
The feasibility of our approach is indicated by the low
participant burden, efficient collection time and agreement
by participants that the methodologies were appropriate for
the cohort. The group in question are typical of RAC in
Australia in relation to age, length of stay and ACFI score
[34], with a low functional status supported by a SPPB sum-
mary score indicative of negative health outcomes [18]. We
involved the RAC facility in the research, using the facility
service manager or director of nursing to identify potential
participants, and coordinating through the facility the delivery
of project information, obtaining of consent and assistance in
data collection. However, while the study had a liberal inclu-
sion criteria that aimed to capture adults independent of dis-
ease or disability [3], ethical and patient difficulty limitations
excluded almost half of the total available population. This
exclusionmay limit the accurate reflection of the population in
question. This is a concern for all end-of-life research, but
unavoidable given the invasive nature of data collection, and
the need for consent and the level of communication in
collecting secondary variables questionnaires included to
identify risk factors [35]. Of further concern is that 67 % of
those randomised to the study declined, commonly affirming
a lack of interest in participation. This could be related to a
number of factors including no participation incentives such
as the benefits gained from a trial intervention (i.e. exercise
intervention), a fear of something new, the need for greater
project understanding by the staff responsible for disseminat-
ing information, as was voiced in the sub-study, and/or cog-
nitive wellbeing, where depression is a known de-motivator to
participation [36–38]. While this low participation rate may
reduce the generalisability of results across RAC population,
they are by no means unusual [36]. Another methodological
limitation was that data were collected within one organisation
and one region of Australia. Organisational differences in
delivery of care and the effect of remote and rural living could
influence levels of sarcopenia [39]. The present work had
budget restriction that influenced recruitment, but to allow
for these differences a broader scope analysis is planned.
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The sub-study analysis of the activPAL monitor was also
found to be feasible in this population. In order to improve the
protocol, facility staff suggested that the sleep diary be sim-
plified, more information provided to centre staff, and greater
communication within centre be encouraged, to minimise
monitors loss and adequately address residents’ questions.
In conclusion, certain limitations restrict blanket data col-
lection in a RAC setting. However, the assessment of
sarcopenia and sarcopenic risk factors such as physical inac-
tivity is feasible among those without ethical considerations
such as palliative status, behavioural or communications prob-
lem. To facilitate projects in this setting, key staff members
need to be involved in the planning and execution of this
process from the beginning in order to ensure their full under-
standing and leadership of the protocol within centres.
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